Literature DB >> 27799345

FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

Josée M Zijlstra1, Coreline N Burggraaff2, Marie José Kersten3, Sally F Barrington.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27799345      PMCID: PMC5394882          DOI: 10.3324/haematol.2016.142752

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

Authors:  René-Olivier Casasnovas; Michel Meignan; Alina Berriolo-Riedinger; Stéphane Bardet; Anne Julian; Catherine Thieblemont; Pierre Vera; Serge Bologna; Josette Brière; Jean-Philippe Jais; Corinne Haioun; Bertrand Coiffier; Franck Morschhauser
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

Authors:  John M M Raemaekers; Marc P E André; Massimo Federico; Theodore Girinsky; Reman Oumedaly; Ercole Brusamolino; Pauline Brice; Christophe Fermé; Richard van der Maazen; Manuel Gotti; Reda Bouabdallah; Catherine J Sebban; Yolande Lievens; Allessandro Re; Aspasia Stamatoullas; Frank Morschhauser; Pieternella J Lugtenburg; Elisabetta Abruzzese; Pierre Olivier; Rene-Olivier Casasnovas; Gustaaf van Imhoff; Tiana Raveloarivahy; Monica Bellei; Thierry van der Borght; Stephane Bardet; Annibale Versari; Martin Hutchings; Michel Meignan; Catherine Fortpied
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.

Authors:  P Ganesan; R Rajendranath; K Kannan; V Radhakrishnan; T S Ganesan; K Udupa; K M Lakshmipathy; V Mahajan; S Sundersingh; S Rajaraman; R Krishnakumar; T G Sagar
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

6.  Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

Authors:  Yvette L Kasamon; Richard L Wahl; Harvey A Ziessman; Amanda L Blackford; Steven N Goodman; Caroline A Fidyk; Kathryn M Rogers; Javier Bolaños-Meade; Michael J Borowitz; Richard F Ambinder; Richard J Jones; Lode J Swinnen
Journal:  Biol Blood Marrow Transplant       Date:  2009-02       Impact factor: 5.742

7.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

8.  Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.

Authors:  N George Mikhaeel; Daniel Smith; Joel T Dunn; Michael Phillips; Henrik Møller; Paul A Fields; David Wrench; Sally F Barrington
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-23       Impact factor: 9.236

9.  PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.

Authors:  Sally F Barrington; Amy A Kirkwood; Antonella Franceschetto; Michael J Fulham; Thomas H Roberts; Helén Almquist; Eva Brun; Karin Hjorthaug; Zaid N Viney; Lucy C Pike; Massimo Federico; Stefano Luminari; John Radford; Judith Trotman; Alexander Fosså; Leanne Berkahn; Daniel Molin; Francesco D'Amore; Donald A Sinclair; Paul Smith; Michael J O'Doherty; Lindsey Stevens; Peter W Johnson
Journal:  Blood       Date:  2016-01-08       Impact factor: 22.113

Review 10.  PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.

Authors:  Sally F Barrington; N George Mikhaeel
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

View more
  3 in total

Review 1.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.

Authors:  Hajira Ilyas; N George Mikhaeel; Joel T Dunn; Fareen Rahman; Henrik Møller; Daniel Smith; Sally F Barrington
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

3.  Hepatic 18F-FDG Uptake Measurements on PET/MR: Impact of Volume of Interest Location on Repeatability.

Authors:  Liran Domachevsky; Hanna Bernstine; Meital Nidam; Dan Stein; Natalia Goldberg; Dorit Stern; Ifat Abadi-Korek; David Groshar
Journal:  Contrast Media Mol Imaging       Date:  2017-05-30       Impact factor: 3.161

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.